Kiniksa Pharmaceuticals Ltd. closed its IPO of 8,477,777 class A common shares at $18 apiece with gross proceeds of $152.6 million.
The company also granted the underwriters an option to buy up to 1,271,666 additional shares.
All of the shares were offered by Bermuda-based Kiniksa, which develops treatments for debilitating diseases with significant unmet medical need.
The shares started trading on the Nasdaq Global Select Market on May 24, under the ticker symbol KNSA.
Goldman Sachs & Co. LLC and J.P. Morgan Securities LLC acted as joint book-running managers for the offering, with JMP Securities LLC and Wedbush Securities Inc. as co-managers.
